HERCULES, Calif.—Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of the 29th StarBright Dye, StarBright Red 670, and an expansion of its current range with 29 additional highly validated antibodies conjugated to StarBright Blue 700 and StarBright Violet 610 Dyes. Including additional human and mouse targets and introducing dog, cow, and pig targets, the new range provides greater choice and flexibility in conventional and full-spectrum multicolor flow cytometry panels, expanding research capabilities across veterinary immunology research.
Offering exceptional brightness with narrow excitation and emission profiles for precise resolution, Bio-Rad’s line of StarBright Dyes provides researchers with validated flow antibodies against key immunology targets conjugated to proprietary fluorescent nanoparticles. StarBright Dyes are compatible with the Bio-Rad ZE5 Cell Analyzer and S3e Cell Sorter, as well as most flow cytometers and experimental protocols, without the need for special buffers. Minimal lot-to-lot variation ensures reproducible and consistent staining, and the dyes are resistant to photobleaching with no loss of signal in fixation.
The additional 29 antibody markers will soon be available on all StarBright Dyes.
"Now totaling 29 dyes for the 355, 405, 488, 561, and 640 nm lasers, the Bio-Rad StarBright Dye range is currently the largest series of dyes for conventional and full spectrum flow cytometry," said Mike Blundell, PhD, Product Manager, Flow Cytometry, Life Science Group, Bio-Rad. "By extending our existing portfolio of 35 antibody markers to include another 29 human, mouse, and now cow, dog, and pig targets, we can offer our customers greater flexibility and choice when designing multicolor flow cytometry panels, including for translational and immunological research in veterinary species."
To learn more about Bio-Rad's StarBright Dyes, visit bio-rad-antibodies.com/flow-cytometry-starbright-dyes.
BIO-RAD and STARBRIGHT are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,200 employees and $2.8 billion in revenues in 2022. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements are based on assumptions and expectations of future events that are subject to risks and uncertainties, which could cause actual results to vary materially from the plans, goals, and expectations expressed in or indicated by the forward-looking statements. These risks and uncertainties include the impact of the COVID-19 pandemic, supply chain risks, global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, reductions in government funding and the capital spending programs of our customers, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Bio-Rad Laboratories, Inc.
Katrina Academia, Inbound Marketing Manager
+44 (0) 7737 543244